Improving Postapproval Drug Safety Surveillance: Getting Better Information Sooner

Overview

Journal Annu Rev Pharmacol Toxicol

Publisher Annual Reviews

Specialties Pharmacology
Toxicology

Date 2014 Oct 9

PMID 25292435

Citations 6

Authors

Sean Hennessy

Brian L Strom

Affiliations

Soon will be listed here.

Abstract

Adverse drug events (ADEs) are an important public health concern, accounting for 5% of all hospital admissions and two-thirds of all complications occurring shortly after hospital discharge. There are often long delays between when a drug is approved and when serious ADEs are identified. Recent and ongoing advances in drug safety surveillance include the establishment of government-sponsored networks of population databases, the use of data mining approaches, and the formal integration of diverse sources of drug safety information. These advances promise to reduce delays in identifying drug-related risks and in providing reassurance about the absence of such risks.

Citing Articles

Predicting Drug Blood-Brain Barrier Penetration with Adverse Event Report Embeddings.

Wu Y, Mower J, Ding X, Li O, Subramanian D, Cohen T AMIA Annu Symp Proc. 2023; 2022:1163-1172.

PMID: 37128462 PMC: 10148361.

Data Mining for Adverse Events of Tumor Necrosis Factor-Alpha Inhibitors in Pediatric Patients: Tree-Based Scan Statistic Analyses of Danish Nationwide Health Data.

Wintzell V, Svanstrom H, Melbye M, Ludvigsson J, Pasternak B, Kulldorff M Clin Drug Investig. 2020; 40(12):1147-1154.

PMID: 33104987 PMC: 7701063. DOI: 10.1007/s40261-020-00977-5.

Advancing regulatory science and assessment of FDA REMS programs: A mixed-methods evaluation examining physician survey response.

Brewer S, Campagna E, Morrato E J Clin Transl Sci. 2019; 3(4):199-209.

PMID: 31660244 PMC: 6799639. DOI: 10.1017/cts.2019.400.

Building a framework for the evaluation of knowledge translation for the Canadian Network for Observational Drug Effect Studies.

Sketris I, Carter N, Traynor R, Watts D, Kelly K Pharmacoepidemiol Drug Saf. 2019; 29 Suppl 1:8-25.

PMID: 30788900 PMC: 6972643. DOI: 10.1002/pds.4738.

Drospirenone-containing oral contraceptives and venous thromboembolism: an analysis of the FAERS database.

Madigan D, Shin J Open Access J Contracept. 2018; 9:29-32.

PMID: 29720882 PMC: 5919164. DOI: 10.2147/OAJC.S161737.

References

Ekstrom N, Schioler L, Svensson A, Eeg-Olofsson K, Jonasson J, Zethelius B . Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open. 2012; 2(4). PMC: 3400073. DOI: 10.1136/bmjopen-2012-001076. View

Nissen S . ADHD drugs and cardiovascular risk. N Engl J Med. 2006; 354(14):1445-8. DOI: 10.1056/NEJMp068049. View

Lindquist M, Edwards I . Risks of non-sedating antihistamines. Lancet. 1997; 349(9061):1322. DOI: 10.1016/S0140-6736(97)26018-6. View

Pirmohamed M, James S, Meakin S, Green C, Scott A, Walley T . Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004; 329(7456):15-9. PMC: 443443. DOI: 10.1136/bmj.329.7456.15. View

Kuhn M, Campillos M, Letunic I, Jensen L, Bork P . A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol. 2010; 6:343. PMC: 2824526. DOI: 10.1038/msb.2009.98. View

Forster A, Murff H, Peterson J, Gandhi T, Bates D . The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med. 2003; 138(3):161-7. DOI: 10.7326/0003-4819-138-3-200302040-00007. View

Lester J, Neyarapally G, Lipowski E, Graham C, Hall M, Dal Pan G . Evaluation of FDA safety-related drug label changes in 2010. Pharmacoepidemiol Drug Saf. 2013; 22(3):302-5. DOI: 10.1002/pds.3395. View

Toh S, Reichman M, Houstoun M, Southworth M, Ding X, Hernandez A . Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med. 2012; 172(20):1582-9. DOI: 10.1001/2013.jamainternmed.34. View

Wynder E, Hall N, Polansky M . Epidemiology of coffee and pancreatic cancer. Cancer Res. 1983; 43(8):3900-6. View

10.

Brown J, Holmes J, Shah K, Hall K, Lazarus R, Platt R . Distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care. Med Care. 2010; 48(6 Suppl):S45-51. DOI: 10.1097/MLR.0b013e3181d9919f. View

11.

Robb M, Racoosin J, Worrall C, Chapman S, Coster T, Cunningham F . Active surveillance of postmarket medical product safety in the Federal Partners' Collaboration. Med Care. 2012; 50(11):948-53. DOI: 10.1097/MLR.0b013e31826c874d. View

12.

Johnson S, Tomlinson G, Hawker G, Granton J, Grosbein H, Feldman B . A valid and reliable belief elicitation method for Bayesian priors. J Clin Epidemiol. 2009; 63(4):370-83. DOI: 10.1016/j.jclinepi.2009.08.005. View

13.

Cooper W, Habel L, Sox C, Chan K, Arbogast P, Cheetham T . ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011; 365(20):1896-904. PMC: 4943074. DOI: 10.1056/NEJMoa1110212. View

14.

Kulldorff M, Dashevsky I, Avery T, Chan A, Davis R, Graham D . Drug safety data mining with a tree-based scan statistic. Pharmacoepidemiol Drug Saf. 2013; 22(5):517-23. DOI: 10.1002/pds.3423. View

15.

Gu Q, Dillon C, Burt V . Prescription drug use continues to increase: U.S. prescription drug data for 2007-2008. NCHS Data Brief. 2010; (42):1-8. View

16.

Reisinger S, Ryan P, OHara D, Powell G, Painter J, Pattishall E . Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases. J Am Med Inform Assoc. 2010; 17(6):652-62. PMC: 3000752. DOI: 10.1136/jamia.2009.002477. View

17.

Dunson D . Commentary: practical advantages of Bayesian analysis of epidemiologic data. Am J Epidemiol. 2001; 153(12):1222-6. DOI: 10.1093/aje/153.12.1222. View

18.

McGuinness M, Talbert R . Phenformin-induced lactic acidosis: a forgotten adverse drug reaction. Ann Pharmacother. 1993; 27(10):1183-7. DOI: 10.1177/106002809302701004. View

19.

Southworth M, Reichman M, Unger E . Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013; 368(14):1272-4. DOI: 10.1056/NEJMp1302834. View

20.

Platt R, Carnahan R, Brown J, Chrischilles E, Curtis L, Hennessy S . The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf. 2012; 21 Suppl 1:1-8. DOI: 10.1002/pds.2343. View